Acuity Pharmaceuticals Inc.
Acuity Pharmaceuticals is developing VEGF-directed RNAi-based therapeutics for ophthalmic diseases, including age-related wet macular degeneration and diabetic retinopathy.
Acuity Pharmaceuticals is developing VEGF-directed RNAi-based therapeutics for ophthalmic diseases, including age-related wet macular degeneration and diabetic retinopathy.